PUBLISHED 11 September 2023 First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared…...
Pei-Yu Chen, BS, MS, PhD, Awarded Two-Year Grant Through VF’s Young Investigator’s Award Program
Pei-Yu Chen, BS, MS, PhD, Senior Research Scientist, Cardiovascular Medicine, at Yale University, has been awarded a two-year grant through the Vasculitis Foundation’s Young Investigator’s Award Program for her study, “siRNA Nanoparticle Targeting Endothelial Cell TGFβ Signaling Against ANCA-Vasculitis.” The aim is to reveal how large a role TGFβ-mediated EndMT…...
David Massicotte-Azarniouch, MD, Awarded Two-Year Grant Through VF’s Young Investigator’s Award Program
David Massicotte-Azarniouch, MD, Assistant Professor at the University of Ottawa and Associate Scientist at the Ottawa Hospital Research Institute in Ontario, Canada, has been awarded a two-year grant through the Vasculitis Foundation’s Young Investigator’s Award Program. The aim of his study, “Steroid Minimization in ANCA-Associated Vasculitis For Safe Effective Treatment…...
Introducing Our 2022-2023 VCRC-VF Fellow: Marta Casal Moura, MD, MSc, MSPH
Marta Casal Moura, MD, MSc, MSPH, began her one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in July 2022. For anti-neutrophil autoantibody (ANCA)-associated vasculitis (AAV), she is studying the predictors of response to plasma exchange in patients who have AAV glomerulonephritis and how histologic scores can predict the response…...
